CXCR3A基因扩增的套细胞淋巴瘤临床病理分析
Clinicopathological analysis of mantle cell lymphoma with CXCR3A gene amplification
陈炜琳 1洪少君 2林燕玲 2纪思灵 2邹宗楷2
作者信息
- 1. 福建医科大学基础医学院,福州 350000
- 2. 福建医科大学附属漳州市医院病理科,漳州 363000
- 折叠
摘要
目的 分析套细胞淋巴瘤(mantle cell lymphoma,MCL)的临床病理特征,探讨C-X-C基序趋化因子受体 3A(C-X-C motif chemokine receptor 3A,CXCR3A)基因扩增致瘤机理和对预后的影响.方法 收集30例MCL患者临床资料,以 30 例反应性淋巴结组织作为对照,对其进行免疫组化及基因检测.结果 30 例MCL中CXCR3A蛋白表达水平≥70%有20 例,其中 2 例伴有CXCR3A基因扩增,信号值分别为38%和 8%.2 例基因扩增患者均为中老年人,为母细胞亚型和多形性变型,临床表现为多部位受累,Ann Arbor分期均为ⅣA期.结论 CXCR3A基因扩增的MCL分期晚,预后差,多为母细胞亚型或多形性变型.对母细胞亚型或多形性变型MCL及高表达CXCR3A的MCL应行FISH检测明确有无CXCR3A基因扩增,以指导临床选择有效靶向用药.
Abstract
Objective To analyze the clinicopathological features of mantle cell lymphoma(MCL),to explore the tumor-causing mechanism of CXCR3A gene amplification and its influence on prognosis.Methods Collecting the clinical data of 30 cases of mantle cell lymphoma,with 30 cases of reactive lymph node tissues as a contrast,which were used for Immunohistochemical and genetic tests.Results Among the 30 cases of MCL,20 had CXCR3A protein expression levels≥70%,with 2 cases were accompanied by CXCR3A gene amplification,and the signal values were 38%and 8%respectively.The two patients with gene amplification were middle-aged and elderly,and they were blastocytic subtype and polymorphic variant,with clinical manifestations of multiple site involvement and Ann Arbor stage of IVA.Conclusion The MCL with CXCR3A gene amplification has a late stage and poor prognosis,and is mostly blastocytic or pleomorphic.CXCR3A may involve in the proliferation,apoptosis and invasion of MCL.Patients with blastotype or polymorphic MCL and high expression of CXCR3A protein should undergo FISH detection to determine whether there is CXCR3A gene amplification,and guide clinical selection of effective targeted drugs.
关键词
套细胞淋巴瘤/C-X-C基序趋化因子受体3AKey words
Mantle cell lymphoma/C-X-C motif chemokine receptor 3A引用本文复制引用
基金项目
福建省自然科学基金(2020J011294)
出版年
2024
NETL
NSTL
万方数据